Balyasny Asset Management L.P. Purchases 2,747 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Balyasny Asset Management L.P. boosted its position in Omnicell, Inc. (NASDAQ:OMCL) by 4.2% during the fourth quarter, HoldingsChannel reports. The fund owned 67,561 shares of the company’s stock after buying an additional 2,747 shares during the quarter. Balyasny Asset Management L.P.’s holdings in Omnicell were worth $3,008,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Smartleaf Asset Management LLC raised its stake in Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock valued at $35,000 after acquiring an additional 273 shares during the period. Summit Investment Advisors Inc. raised its stake in Omnicell by 6.9% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,774 shares of the company’s stock valued at $213,000 after acquiring an additional 307 shares during the period. Van ECK Associates Corp increased its position in shares of Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after buying an additional 315 shares during the period. First Horizon Advisors Inc. increased its position in shares of Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock valued at $59,000 after buying an additional 355 shares during the period. Finally, Redmond Asset Management LLC increased its position in shares of Omnicell by 0.3% during the fourth quarter. Redmond Asset Management LLC now owns 121,209 shares of the company’s stock valued at $5,396,000 after buying an additional 371 shares during the period. 97.70% of the stock is currently owned by institutional investors.

Omnicell Stock Up 1.9%

OMCL stock opened at $25.88 on Monday. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The company’s 50 day moving average is $32.28 and its 200 day moving average is $39.97. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of 95.86, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. Omnicell, Inc. has a 1-year low of $22.66 and a 1-year high of $55.75.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.10. The company had revenue of $269.67 million for the quarter, compared to analysts’ expectations of $260.18 million. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Omnicell’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.03 earnings per share. Sell-side analysts predict that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Analyst Ratings Changes

OMCL has been the topic of several analyst reports. Wells Fargo & Company decreased their price target on Omnicell from $38.00 to $31.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 7th. StockNews.com cut Omnicell from a “buy” rating to a “hold” rating in a research report on Saturday, May 3rd. JPMorgan Chase & Co. decreased their price target on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday, March 20th. Finally, Benchmark decreased their price target on Omnicell from $62.00 to $40.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Omnicell has an average rating of “Hold” and a consensus price target of $45.83.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.